Cannabis Bioscience International Holdings EBIT

The latest EBIT for CBIH is $-310K as of February 2026. That compares with $-340K in the prior-year period — up 9.2% year over year. That is below the sector sector average of $2.5T. Investors often review this figure alongside Cannabis Bioscience International Holdings's historical trend and sector peers before judging valuation or financial health.

Over the past year, CBIH's EBIT moved from $-340K to $-310K — a 9.2% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Cannabis Bioscience International Holdings's operating scale or balance-sheet position.

Against its sector companies, CBIH currently prints $-310K for EBIT, while the sector average sits near $2.5T. That is roughly 100.0% below the sector mean. Large gaps often invite a closer look at Cannabis Bioscience International Holdings's growth, margins, and balance sheet.

A EBIT figure of $-310K for CBIH is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The sector average is about $2.5T. Explore the charts below for those layers of context.

After noting CBIH's EBIT ($-310K), review year-over-year change from $-340K, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.